“A GREAT OFFICE FOR LICENSING“ IAM MAGAZINE 2016
Congratulations to our client, IOPtima Ltd., on the completion of the second stage of its acquisition transaction with Chengdu Kanghong Pharma Group Co. Ltd. Horn & Co. team was led by Yuval Horn, Paz Abercohen and Uri Dotan.
Horn & Co. represented Spacemesh in a Series A $15M financing round led by Polychain Ventures, with participation from the world’s leading blockchain oriented investment funds. The Horn & Co. team was led by Yuval Horn, Ohad Mamann and Maya Weiss Donin. Tomer Afek, Aviv Eyal and Ifat Linur – congratulations on this impressive milestone!
Proud to lead the list of top Israeli firms specializing in Hi-tech with an equal number of female and male partners, as described in this interesting article by @themarker.
Yuval Horn and Keren Kanir of Horn & Co. represented Anima Biotech in an exclusive collaboration agreement with Eli Lilly, with a total deal value exceeding $1 billion.
Proud to be ranked, again, by IAM Magazine (Intellectual Asset Management) as one of top 4 “highly recommended” Israeli firms in intellectual property transactions: “Horn & Co’s small size belies the reputation it enjoys with regard to the commercialisation of intellectual property.
Congratulations to our client, Zebra Medical for closing an impressive $30M financing round led by aMoon Ventures, with participation from Aurum, Johnson & Johnson Innovation and additional new and current investors.
Yuval Horn chosen as “Thought Leader” of Life Sciences Transactions by Who’s Who Legal: Life Sciences 2018.
Horn & Co. has been recognized again by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences.
Yuval Horn and Ohad Mamann of Horn & Co. represented Pontifax, who led a €16 million Series A round and restructuring in ABAC Therapeutics, Inc.